Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether plasma exchange as well as immunosuppressive therapy are effective in reducing death and end-stage renal disease (ESRD). The trial will also study whether a reduced cumulative dosing regimen of glucocorticoids is as effective as a standard disease regimen.

The FDA-OOPD is one of the funding sources for this study.


Clinical Trial Description

Granulomatosis with polyangiitis (Wegener's) (WG) and microscopic polyangiitis (MPA) are syndromes of primary systemic vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). Together, these syndromes are grouped as ANCA-associated systemic vasculitis (AAV).

Plasma exchange, a method of rapidly removing potentially pathogenic ANCA and other mediators of inflammation and coagulation, has shown promise as an adjunctive therapy in AAV to improve early disease control and improve rates of renal recovery in severe disease. Glucocorticoids (steroids) are a standard of care in the treatment of AAV. High doses of glucocorticoids early in disease, although reduce disease activity due to their anti-inflammatory and immunosuppressive properties, also increase the risk of infection, particularly in the elderly and in the presence of uremia. There is no randomized trial data to guide glucocorticoids dosing.

Patients with severe new or relapsing AAV and pulmonary hemorrhage and/or renal disease will be eligible for this trial.

Subjects participating in this study will be randomized to receive one of the following groups;

1. Plasma exchange - 7 exchanges and, either standard or low-dose glucocorticoids or

2. No plasma exchange and, either standard or low-dose glucocorticoids

All studies will receive standard remission-induction therapy with either cyclophosphamide or rituximab. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03919825
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase Phase 3
Start date May 2010
Completion date August 31, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03920722 - Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Phase 3
Terminated NCT03712345 - Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA Phase 2
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Completed NCT00987389 - Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Phase 3
Completed NCT02507024 - The ANCA Vasculitis Questionnaire (AAV-PRO©) N/A
Recruiting NCT03004326 - Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Completed NCT03895801 - Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Phase 2